What is the Purpose of this Study?
Primary Objective: Pathological complete response (pCR) rate Secondary Objectives: Event-free survival (EFS) Overall survival (OS) Patient-reported outcomes (PRO) Immune biomarkers
Eligibility
Not Available
Where can I participate?
- CS Cancer at Beverly Hills : Nikki Kem-Bernard
- CS Cancer at Cedars-Sinai Medical Center : Nikki Kem-Bernard
- Hunt Cancer Institute, an Affiliate of Cedars-Sinai Cancer
What is the full name of this clinical trial?
IIT2024-09-YUAN-NeoIVO: Phase II Trial of Ivonescimab in combination with carboplatin + docetaxel in Patients with Early Stage Triple Negative Breast Cancer